<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Crit Care Med</journal-id><journal-id journal-id-type="iso-abbrev">Indian J Crit Care Med</journal-id><journal-id journal-id-type="publisher-id">IJCCM</journal-id><journal-title-group><journal-title>Indian Journal of Critical Care Medicine : Peer-reviewed, Official Publication of Indian Society of Critical Care Medicine</journal-title></journal-title-group><issn pub-type="ppub">0972-5229</issn><issn pub-type="epub">1998-359X</issn><publisher><publisher-name>Medknow Publications &amp; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25624646</article-id><article-id pub-id-type="pmc">4296406</article-id><article-id pub-id-type="publisher-id">IJCCM-19-21</article-id><article-id pub-id-type="doi">10.4103/0972-5229.148635</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>The comparison of extemporaneous preparations of omeprazole, pantoprazole oral suspension and intravenous pantoprazole on the gastric pH of critically ill-patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dabiri</surname><given-names>Yasamin</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Fahimi</surname><given-names>Fanak</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Jamaati</surname><given-names>Hamidreza</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Hashemian</surname><given-names>Seyed Mohammad Reza</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="corresp" rid="cor1"></xref></contrib></contrib-group><aff id="aff1"><bold>From:</bold><label>1</label>Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran</aff><aff id="aff2"><label>2</label>Chronic Respiratory Disease Research Center, National Research Institute of Tuberculosis and Lung Diseases, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran</aff><aff id="aff3"><label>3</label>Tobacco Prevention and Control Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran</aff><aff id="aff4"><label>4</label>Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran</aff><author-notes><corresp id="cor1"><bold>Correspondence:</bold> Prof. Seyed Mohammad Reza Hashemian, #20, JAVANSHIR, LAVIZAN, baharan TWR, TEHRAN, 16688 E-mail: <email xlink:href="smrhashemian@sbmu.ac.ir">smrhashemian@sbmu.ac.ir</email></corresp></author-notes><pub-date pub-type="ppub"><month>1</month><year>2015</year></pub-date><volume>19</volume><issue>1</issue><fpage>21</fpage><lpage>26</lpage><permissions><copyright-statement>Copyright: © Indian Journal of Critical Care Medicine</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title><offsets xml_i="3918" xml_f="3929" txt_i="11" txt_f="22">Background:</offsets></title><p><offsets xml_i="3940" xml_f="4369" txt_i="23" txt_f="452">Stress-related mucosal disease occurs in many critically ill-patients within 24 h of admission. Proton pump inhibitor therapy has been documented to produce more potent inhibition of gastric acid secretion than histamine 2 receptor antagonists. This study aimed to compare extemporaneous preparations of omeprazole, pantoprazole oral suspension and intravenous (IV) pantoprazole on the gastric pH in intensive care unit patients.</offsets></p></sec><sec id="st2"><title><offsets xml_i="4400" xml_f="4422" txt_i="454" txt_f="476">Materials and Methods:</offsets></title><p><offsets xml_i="4433" xml_f="5155" txt_i="477" txt_f="1199">This was a randomized single-blind-study. Patients of ≥ 16 years of age with a nasogastric tube, who required mechanical ventilation for ≥ 48 h, were eligible for inclusion. The excluded patients were those with active gastrointestinal bleeding, known allergy to omeprazole and pantoprazole and those intolerant to the nasogastric tube. Fifty-six patients were randomized to treatment with omeprazole suspension 2 mg/ml (40 mg every day), pantoprazole suspension 2 mg/ml (40 mg every day) and IV pantoprazole (40 mg every day) for up to 14 days. Gastric aspirates were sampled before and 1-2.5 h after the drug administration for the pH measurement using an external pH meter. Data were analyzed using SPSS (version 21.0).</offsets></p></sec><sec id="st3"><title><offsets xml_i="5186" xml_f="5194" txt_i="1201" txt_f="1209">Results:</offsets></title><p><offsets xml_i="5205" xml_f="5540" txt_i="1210" txt_f="1545">In this study, 56 critically ill-patients (39 male, 17 female, mean age: 61.5 ± 15.65 years) were followed for the control of the gastric pH. On each of the 14 trial days the mean of the gastric pH alteration was significantly higher in omeprazole and pantoprazole suspension-treated patients than in IV pantoprazole-treated patients (</offsets><italic><offsets xml_i="5548" xml_f="5549" txt_i="1545" txt_f="1546">P</offsets></italic><offsets xml_i="5558" xml_f="5571" txt_i="1546" txt_f="1556"> &lt; 0.001).</offsets></p></sec><sec id="st4"><title><offsets xml_i="5602" xml_f="5613" txt_i="1558" txt_f="1569">Conclusion:</offsets></title><p><offsets xml_i="5624" xml_f="5737" txt_i="1570" txt_f="1683">Omeprazole and pantoprazole oral suspension are more effective than IV pantoprazole in increasing the gastric pH.</offsets></p></sec></abstract><kwd-group><kwd>Gastrointestinal bleeding</kwd><kwd>omeprazole</kwd><kwd>pantoprazole</kwd><kwd>stress-related mucosal disease</kwd><kwd>suspension</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title><offsets xml_i="5993" xml_f="6005" txt_i="1692" txt_f="1704">Introduction</offsets></title><p><offsets xml_i="6016" xml_f="6184" txt_i="1705" txt_f="1873">Stress-related mucosal damage can be turned up in almost 100% of the patients admitted to intensive care units (ICUs) and may be developed within 24 h after admission.[</offsets><xref rid="ref1" ref-type="bibr"><offsets xml_i="6217" xml_f="6218" txt_i="1873" txt_f="1874">1</offsets></xref><xref rid="ref2" ref-type="bibr"><offsets xml_i="6258" xml_f="6259" txt_i="1874" txt_f="1875">2</offsets></xref><offsets xml_i="6266" xml_f="6571" txt_i="1875" txt_f="2180">] The incidence of clinically important gastrointestinal (GI) bleeding, indicated as overt bleeding complicated by hemodynamic instability, low hemoglobin, and/or need for blood transfusion from stress-related mucosal disease (SRMD) is 3.5% in the ICU patients who are mechanically ventilated for ≥ 48 h.[</offsets><xref rid="ref3" ref-type="bibr"><offsets xml_i="6604" xml_f="6605" txt_i="2180" txt_f="2181">3</offsets></xref><offsets xml_i="6612" xml_f="6756" txt_i="2181" txt_f="2325">] In addition, this type of ulceration is accompanied by increasing the risk of mortality. Moreover, it prolongs the length of stay in the ICU.[</offsets><xref rid="ref3" ref-type="bibr"><offsets xml_i="6789" xml_f="6790" txt_i="2325" txt_f="2326">3</offsets></xref><offsets xml_i="6797" xml_f="6798" txt_i="2326" txt_f="2327">]</offsets></p><p><offsets xml_i="6805" xml_f="6969" txt_i="2328" txt_f="2492">Although ischemia of the gastric mucosa leads to SRMD, the significant role of gastric acid in the development of mucosal damage and bleeding could not be ignored.[</offsets><xref rid="ref4" ref-type="bibr"><offsets xml_i="7002" xml_f="7003" txt_i="2492" txt_f="2493">4</offsets></xref><xref rid="ref5" ref-type="bibr"><offsets xml_i="7043" xml_f="7044" txt_i="2493" txt_f="2494">5</offsets></xref><xref rid="ref6" ref-type="bibr"><offsets xml_i="7084" xml_f="7085" txt_i="2494" txt_f="2495">6</offsets></xref><offsets xml_i="7092" xml_f="7222" txt_i="2495" txt_f="2625">] Thus, early preventive prophylaxis of the probable GI bleeding, by means of acid-reducing agents, in these patients is rational.</offsets></p><p><offsets xml_i="7229" xml_f="7455" txt_i="2626" txt_f="2852">Proton pump inhibitors (PPIs) are the most potent and long-lasting medications used for this purpose. It is now generally believed that the aim of acid suppression as the prophylaxis of SRMD is to maintain gastric pH above 4.[</offsets><xref rid="ref7" ref-type="bibr"><offsets xml_i="7488" xml_f="7489" txt_i="2852" txt_f="2853">7</offsets></xref><offsets xml_i="7496" xml_f="7918" txt_i="2853" txt_f="3275">] Omeprazole, which is the first member of the PPI class, is commercially available as a delayed-release capsule and is formulated as enteric-coated granules to be protected against acid degradation. This formulation of oral PPIs put constraints on their usage in critically ill-patients who are NPO and unable to swallow the solid forms of drugs and those who experience an alteration in GI function after major surgery.[</offsets><xref rid="ref8" ref-type="bibr"><offsets xml_i="7951" xml_f="7952" txt_i="3275" txt_f="3276">8</offsets></xref><offsets xml_i="7959" xml_f="8304" txt_i="3276" txt_f="3621">] An alternative method of delivery that allows an aqueous administration, while protecting the intact drug from acid degradation, is omeprazole suspension. Omeprazole suspension, which is administered to critically ill-patients on mechanical ventilation, has been shown to prevent upper GI bleeding as well as maintaining gastric pH above 5.5.[</offsets><xref rid="ref1" ref-type="bibr"><offsets xml_i="8337" xml_f="8338" txt_i="3621" txt_f="3622">1</offsets></xref><offsets xml_i="8345" xml_f="8471" txt_i="3622" txt_f="3748">] The anti-secretory effect of intravenous (IV) pantoprazole, another drug of this family, has been shown in several studies.[</offsets><xref rid="ref9" ref-type="bibr"><offsets xml_i="8504" xml_f="8505" txt_i="3748" txt_f="3749">9</offsets></xref><xref rid="ref10" ref-type="bibr"><offsets xml_i="8546" xml_f="8548" txt_i="3749" txt_f="3751">10</offsets></xref><xref rid="ref11" ref-type="bibr"><offsets xml_i="8589" xml_f="8591" txt_i="3751" txt_f="3753">11</offsets></xref><offsets xml_i="8598" xml_f="8860" txt_i="3753" txt_f="4015">] Pantoprazole is chemically more stable than other PPIs in higher pH conditions. It also provides earlier healing and superior pain relief in peptic ulcer and gastroesophageal reflux disease compared with omeprazole or histamine 2 receptor antagonists (H2RAs).[</offsets><xref rid="ref12" ref-type="bibr"><offsets xml_i="8894" xml_f="8896" txt_i="4015" txt_f="4017">12</offsets></xref><xref rid="ref13" ref-type="bibr"><offsets xml_i="8937" xml_f="8939" txt_i="4017" txt_f="4019">13</offsets></xref><offsets xml_i="8946" xml_f="8947" txt_i="4019" txt_f="4020">]</offsets></p><p><offsets xml_i="8954" xml_f="9313" txt_i="4021" txt_f="4380">The main objective of this study was to evaluate the effect of an extemporaneously formulated pantoprazole suspension, omeprazole suspension and commercially available IV pantoprazole on the gastric pH of critically ill-patients. The secondary objective was to assess the incidence of upper GI bleeding and ventilator-associated pneumonia in the ICU patients.</offsets></p></sec><sec sec-type="materials|methods" id="sec1-2"><title><offsets xml_i="9376" xml_f="9397" txt_i="4382" txt_f="4403">Materials and Methods</offsets></title><sec id="sec2-1"><title></title><sec id="sec3-1"><title><offsets xml_i="9461" xml_f="9469" txt_i="4405" txt_f="4413">Subjects</offsets></title><p><offsets xml_i="9480" xml_f="9897" txt_i="4414" txt_f="4831">The inclusion criteria were as follow: Patients older than 16 years old who were admitted to medical and surgical ICUs of National Research Institute of Tuberculosis and Lung Diseases (NRITLD) with an anticipated stay of longer than 72 h. In addition, those who required mechanical ventilation for more than 48 h, had an Acute Physiology and Chronic Health Evaluation (APACHE II) score of bigger than 11 at baseline,[</offsets><xref rid="ref14" ref-type="bibr"><offsets xml_i="9931" xml_f="9933" txt_i="4831" txt_f="4833">14</offsets></xref><offsets xml_i="9940" xml_f="10081" txt_i="4833" txt_f="4974">] and had a nasogastric or orogastric tube in place. Participants were eligible for GI prophylaxis based on up to date defined risk factors.[</offsets><xref rid="ref15" ref-type="bibr"><offsets xml_i="10115" xml_f="10117" txt_i="4974" txt_f="4976">15</offsets></xref><offsets xml_i="10124" xml_f="10771" txt_i="4976" txt_f="5623">] Other acid-reducing agents, including H2RAs and antacids, which may alter the gastric pH, were removed from the patient's medications before the trial. Patients were excluded from the study if any of the following criteria were met: (1) A status of “no cardiopulmonary resuscitation;” (2) delay longer than 48 h from the time of initial eligibility; (3) known hypersensitivity to PPIs including omeprazole or pantoprazole; (4) history of gastric surgery; (5) active GI bleeding; (6) significant risk of swallowing blood; (7) admission for upper GI surgery; (8) inability to take a suspension by nasogastric tube; and (9) end-stage liver disease.</offsets></p><p><offsets xml_i="10778" xml_f="10924" txt_i="5624" txt_f="5770">If any of the following events were the case, the trial would stop: (1) Removal of a nasogastric tube (2) death; and (3) discharge from the unit [</offsets><xref ref-type="fig" rid="F1"><offsets xml_i="10954" xml_f="10962" txt_i="5770" txt_f="5778">Figure 1</offsets></xref><offsets xml_i="10969" xml_f="10971" txt_i="5778" txt_f="5780">].</offsets></p><fig id="F1" position="float"><label><offsets xml_i="11012" xml_f="11020" txt_i="5781" txt_f="5789">Figure 1</offsets></label><caption><p><offsets xml_i="11040" xml_f="11086" txt_i="5789" txt_f="5835">Reasons of discontinuation in treatment groups</offsets></p></caption><graphic xlink:href="IJCCM-19-21-g001"></graphic></fig></sec><sec id="sec3-2"><title><offsets xml_i="11185" xml_f="11197" txt_i="5837" txt_f="5849">Study design</offsets></title><p><offsets xml_i="11208" xml_f="11412" txt_i="5850" txt_f="6054">The study was approved by the NRITLD Ethics Committee. Fifty-six patients were enrolled into this study. The study was a randomized, single-blind, uni-center study between October 2012 and September 2013.</offsets></p><p><offsets xml_i="11419" xml_f="11912" txt_i="6055" txt_f="6548">Patients were randomly placed in three groups based on a random number table. Group A received immediate-release omeprazole oral suspension 2 mg/ml (40 mg daily), Group B received immediate-release pantoprazole oral suspension 2 mg/ml (40 mg daily) and Group C received IV pantoprazole (40 mg daily) for at least 24 h and up to 14 days depending on their survival, length of stay and removal of nasogastric tube. Omeprazole and pantoprazole suspension were administered via a nasogastric tube.</offsets></p></sec><sec id="sec3-3"><title><offsets xml_i="11946" xml_f="11992" txt_i="6550" txt_f="6596">Extemporaneously preparation of the suspension</offsets></title><p><offsets xml_i="12003" xml_f="12304" txt_i="6597" txt_f="6898">A 20 mg omeprazole capsule was opened, and the granules were added to 10 ml of 8.4% sodium bicarbonate to achieve a final concentration of 2 mg/ml. The enteric-coated omeprazole granules were allowed to disintegrate with gentle agitation, suspending the omeprazole in the sodium bicarbonate solution.[</offsets><xref rid="ref16" ref-type="bibr"><offsets xml_i="12338" xml_f="12340" txt_i="6898" txt_f="6900">16</offsets></xref><offsets xml_i="12347" xml_f="12612" txt_i="6900" txt_f="7165">] For the preparation of pantoprazole suspension, a similar procedure was followed. A 40 mg pantoprazole enteric-coated tablet triturated into a homogeny powder. The powder added to 20 ml of 8.4% sodium bicarbonate solution resulting in a concentration of 2 mg/ml.[</offsets><xref rid="ref16" ref-type="bibr"><offsets xml_i="12646" xml_f="12648" txt_i="7165" txt_f="7167">16</offsets></xref><offsets xml_i="12655" xml_f="12656" txt_i="7167" txt_f="7168">]</offsets></p></sec><sec id="sec3-4"><title><offsets xml_i="12690" xml_f="12706" txt_i="7170" txt_f="7186">Gastric pH assay</offsets></title><p><offsets xml_i="12717" xml_f="12883" txt_i="7187" txt_f="7353">Monitoring of gastric acidity (pH) began immediately before and 1-2.5 h after the drug administration in every trial day by means of an external pH meter (AZ 86502).[</offsets><xref rid="ref17" ref-type="bibr"><offsets xml_i="12917" xml_f="12919" txt_i="7353" txt_f="7355">17</offsets></xref><offsets xml_i="12926" xml_f="13141" txt_i="7355" txt_f="7570">] Due to the intermittent enteral feeding via the NG tube, enteral feeding was held for 2 h before the drug was given. If gastric aspirate contained “coffee-grounds” material, the sample was tested with gastroccult.</offsets></p><p><offsets xml_i="13148" xml_f="13432" txt_i="7571" txt_f="7855">The primary end point included the mean gastric pH on each trial day. Additional end points were assessment of the incidence of upper GI bleeding and nosocomial pneumonia. For the diagnosis of nosocomial pneumonia, we used Clinical Pulmonary Infection Score (CPIS) described by Pugin </offsets><italic><offsets xml_i="13440" xml_f="13445" txt_i="7855" txt_f="7860">et al</offsets></italic><offsets xml_i="13454" xml_f="13456" txt_i="7860" txt_f="7862">.[</offsets><xref rid="ref18" ref-type="bibr"><offsets xml_i="13490" xml_f="13492" txt_i="7862" txt_f="7864">18</offsets></xref><offsets xml_i="13499" xml_f="13924" txt_i="7864" txt_f="8289">] CPIS consists of six easily obtainable clinical and laboratory variables: (1) Body temperature, (2) blood leukocyte count and number of band forms, (3) character of tracheal secretions (purulent or not) and quantity of tracheal aspirates, (4) microscopic examination (Gram-stain) and semi-quantitative culture results of the bronchial secretions, (5) ratio of arterial oxygen tension and inspiratory fraction of oxygen (PaO</offsets><sub><offsets xml_i="13929" xml_f="13930" txt_i="8289" txt_f="8290">2</offsets></sub><offsets xml_i="13936" xml_f="13941" txt_i="8290" txt_f="8295"> /FiO</offsets><sub><offsets xml_i="13946" xml_f="13947" txt_i="8295" txt_f="8296">2</offsets></sub><offsets xml_i="13953" xml_f="14039" txt_i="8296" txt_f="8382">), (6) interpretations of chest X-ray, and the use of antibiotics. According to Pugin </offsets><italic><offsets xml_i="14047" xml_f="14052" txt_i="8382" txt_f="8387">et al</offsets></italic><offsets xml_i="14061" xml_f="14152" txt_i="8387" txt_f="8478">., a CPIS score ≥ 6 is considered as an excellent diagnostic tool for nosocomial pneumonia.</offsets></p></sec><sec id="sec3-5"><title><offsets xml_i="14186" xml_f="14206" txt_i="8480" txt_f="8500">Statistical analysis</offsets></title><p><offsets xml_i="14217" xml_f="14557" txt_i="8501" txt_f="8841">For statistical analysis, raw data acquired of 56 patients (18 patients per omeprazole suspension and IV pantoprazole and 20 patients per pantoprazole suspension group) was entered into  SPSS (version 21.0). Comparisons of categorical data were done using the Chi-square test, and parametric numerical data were analyzed by the ANOVA test. </offsets><italic><offsets xml_i="14565" xml_f="14566" txt_i="8841" txt_f="8842">P</offsets></italic><offsets xml_i="14575" xml_f="14781" txt_i="8842" txt_f="9045"> &lt; 0.05 was considered as statistically significant. Gastric pH was compared in all three groups utilizing mean difference of gastric pH alteration before and after treatment by Generalized Linear Model.</offsets></p></sec></sec></sec><sec sec-type="results" id="sec1-3"><title><offsets xml_i="14846" xml_f="14853" txt_i="9049" txt_f="9056">Results</offsets></title><p><offsets xml_i="14864" xml_f="14977" txt_i="9057" txt_f="9170">The “baseline demographics” and the “baseline clinical characteristics” of 56 participants represented in Tables </offsets><xref ref-type="table" rid="T1"><offsets xml_i="15009" xml_f="15010" txt_i="9170" txt_f="9171">1</offsets></xref><offsets xml_i="15017" xml_f="15022" txt_i="9171" txt_f="9176"> and </offsets><xref ref-type="table" rid="T2"><offsets xml_i="15054" xml_f="15055" txt_i="9176" txt_f="9177">2</offsets></xref><offsets xml_i="15062" xml_f="15076" txt_i="9177" txt_f="9191"> respectively.</offsets></p><table-wrap id="T1" position="float"><label><offsets xml_i="15124" xml_f="15131" txt_i="9192" txt_f="9199">Table 1</offsets></label><caption><p><offsets xml_i="15151" xml_f="15172" txt_i="9199" txt_f="9220">Baseline demographics</offsets></p></caption><graphic xlink:href="IJCCM-19-21-g002"></graphic></table-wrap><table-wrap id="T2" position="float"><label><offsets xml_i="15292" xml_f="15299" txt_i="9221" txt_f="9228">Table 2</offsets></label><caption><p><offsets xml_i="15319" xml_f="15355" txt_i="9228" txt_f="9264">Clinical characteristics at baseline</offsets></p></caption><graphic xlink:href="IJCCM-19-21-g003"></graphic></table-wrap><p><offsets xml_i="15434" xml_f="16197" txt_i="9265" txt_f="10028">There was no statistically significant difference in the baseline demographics and clinical characteristics among the groups. The mean (standard deviation [SD]) age for a total population was 61.50 (15.65) years, which 48.21% were older than 65 years. For the whole population, baseline mean (SD) APACHE II score was 23.55 (7.40). All the participants had acute respiratory failure as a risk factor whereas none of them met trauma and shock. The majority of patients (48.21%) had sepsis as a presenting risk factor. Other risk factors included acute renal failure (35.71%), coagulopathy (28.57%), and surgery (5.36%). The baseline gastric pH had no statistically difference between the treatment groups with a mean (SD) pH for the total population of 5.52 (1.06).</offsets></p><p><xref ref-type="table" rid="T3"><offsets xml_i="16236" xml_f="16243" txt_i="10029" txt_f="10036">Table 3</offsets></xref><offsets xml_i="16250" xml_f="16511" txt_i="10036" txt_f="10297"> presents the results of our primary end point-mean gastric pH after drug administration-on each trial day. Due to the important effect of the baseline pH on the gastric pH after the drug administration, we also calculated the mean of the gastric pH alteration.</offsets></p><table-wrap id="T3" position="float"><label><offsets xml_i="16559" xml_f="16566" txt_i="10298" txt_f="10305">Table 3</offsets></label><caption><p><offsets xml_i="16586" xml_f="16631" txt_i="10305" txt_f="10350">Mean gastric pH after the drug administration</offsets></p></caption><graphic xlink:href="IJCCM-19-21-g004"></graphic></table-wrap><p><offsets xml_i="16710" xml_f="16933" txt_i="10351" txt_f="10574">On every 14 days, the mean gastric pH alteration values were significantly higher in omeprazole and pantoprazole suspension group after prophylaxis with each of the medications compared to IV pantoprazole-treated patients (</offsets><italic><offsets xml_i="16941" xml_f="16942" txt_i="10574" txt_f="10575">P</offsets></italic><offsets xml_i="16951" xml_f="16975" txt_i="10575" txt_f="10596"> &lt; 0.001, all days) [</offsets><xref ref-type="fig" rid="F2"><offsets xml_i="17005" xml_f="17013" txt_i="10596" txt_f="10604">Figure 2</offsets></xref><offsets xml_i="17020" xml_f="17022" txt_i="10604" txt_f="10606">].</offsets></p><fig id="F2" position="float"><label><offsets xml_i="17063" xml_f="17071" txt_i="10607" txt_f="10615">Figure 2</offsets></label><caption><p><offsets xml_i="17091" xml_f="17101" txt_i="10615" txt_f="10625">Mean of pH</offsets></p></caption><graphic xlink:href="IJCCM-19-21-g005"></graphic></fig><sec id="sec2-2"><title></title><sec id="sec3-6"><title><offsets xml_i="17226" xml_f="17263" txt_i="10627" txt_f="10664">Average time to achieve the target pH</offsets></title><p><offsets xml_i="17274" xml_f="17786" txt_i="10665" txt_f="11177">We considered mean of gastric pH alteration ≥ 1 as a target. Average time to get this pH for the total population was 1.24 ± 0.61 days (1.35 ± 0.79 days in Group A, 1.17 ± 0.51 days in Group B and 1.2 ± 0.52 days in Group C). In addition, 83.6% of patients achieved the target pH after the first dose administration (76.5% in pantoprazole suspension group, 88.9% in omeprazole suspension group and 85% who received pantoprazole suspension). There was no statistically significant difference between three groups.</offsets></p></sec><sec id="sec3-7"><title><offsets xml_i="17820" xml_f="17864" txt_i="11179" txt_f="11223">Incidence of upper gastrointestinal bleeding</offsets></title><p><offsets xml_i="17875" xml_f="18187" txt_i="11224" txt_f="11536">Protocol defined upper GI bleeding occurred in 3 (5.6%) patients from the total population. Two patients (11.1%) were in the IV pantoprazole-treated patients, and one of them (5.6%) was in the omeprazole suspension group. No patient in pantoprazole suspension-treated group was identified with upper GI bleeding.</offsets></p></sec><sec id="sec3-8"><title><offsets xml_i="18221" xml_f="18243" txt_i="11538" txt_f="11560">Incidence of pneumonia</offsets></title><p><offsets xml_i="18254" xml_f="18485" txt_i="11561" txt_f="11792">Sixteen (88.9%) patients from IV pantoprazole treated group, 14 (77.8%) patients from omeprazole suspension-treated group and 17 (85%) patients who had received pantoprazole suspension were diagnosed as having nosocomial pneumonia.</offsets></p></sec></sec></sec><sec sec-type="discussion" id="sec1-4"><title><offsets xml_i="18553" xml_f="18563" txt_i="11796" txt_f="11806">Discussion</offsets></title><p><offsets xml_i="18574" xml_f="18854" txt_i="11807" txt_f="12087">This study demonstrated that extemporaneously prepared omeprazole and pantoprazole oral suspension produced higher mean gastric pH values than IV pantoprazole. There was statistically significant difference between omeprazole and pantoprazole oral suspension and IV pantoprazole (</offsets><italic><offsets xml_i="18862" xml_f="18863" txt_i="12087" txt_f="12088">P</offsets></italic><offsets xml_i="18872" xml_f="18886" txt_i="12088" txt_f="12099"> &lt; 0.001) [</offsets><xref ref-type="table" rid="T3"><offsets xml_i="18918" xml_f="18925" txt_i="12099" txt_f="12106">Table 3</offsets></xref><offsets xml_i="18932" xml_f="18934" txt_i="12106" txt_f="12108">].</offsets></p><p><offsets xml_i="18941" xml_f="18950" txt_i="12109" txt_f="12118">Phillips </offsets><italic><offsets xml_i="18958" xml_f="18963" txt_i="12118" txt_f="12123">et al</offsets></italic><offsets xml_i="18972" xml_f="19520" txt_i="12123" txt_f="12668">. studied a 20 ml dose of 2 mg/ml omeprazole suspension (containing 40 mg of omeprazole) initially, followed by 20 ml dose administered 6-8 h later, then 10 ml (20 mg) dose for stress-related mucosal damage in 75 patients undergoing mechanical ventilation who had at least one additional risk factor for upper GI bleeding. They observed that the omeprazole suspension increased gastric pH more than 7.1, maintained gastric pH &gt; 5.5 and prevented clinically significant upper GI bleeding without increasing the incidence of nosocomial pneumonia.[</offsets><xref rid="ref8" ref-type="bibr"><offsets xml_i="19553" xml_f="19554" txt_i="12668" txt_f="12669">8</offsets></xref><offsets xml_i="19561" xml_f="19612" txt_i="12669" txt_f="12720">] These findings are completely in line with Lasky </offsets><italic><offsets xml_i="19620" xml_f="19625" txt_i="12720" txt_f="12725">et al</offsets></italic><offsets xml_i="19634" xml_f="19841" txt_i="12725" txt_f="12932">. study on 60 participants who assessed the effect of omeprazole suspension in preventing clinically significant upper GI bleeding and in preventing stress ulcers in mechanically ventilated trauma patients.[</offsets><xref rid="ref19" ref-type="bibr"><offsets xml_i="19875" xml_f="19877" txt_i="12932" txt_f="12934">19</offsets></xref><offsets xml_i="19884" xml_f="19885" txt_i="12934" txt_f="12935">]</offsets></p><p><offsets xml_i="19892" xml_f="19936" txt_i="12936" txt_f="12980">In a randomized, double-blind trial, Conrad </offsets><italic><offsets xml_i="19944" xml_f="19949" txt_i="12980" txt_f="12985">et al</offsets></italic><offsets xml_i="19958" xml_f="20164" txt_i="12985" txt_f="13191">. found that immediate-release omeprazole oral suspension is more effective than a continuous infusion of cimetidine in increasing gastric pH and in preventing upper GI bleeding of critically ill patients.[</offsets><xref rid="ref17" ref-type="bibr"><offsets xml_i="20198" xml_f="20200" txt_i="13191" txt_f="13193">17</offsets></xref><offsets xml_i="20207" xml_f="20257" txt_i="13193" txt_f="13243">] In a smaller, un-blinded, randomized trial Levy </offsets><italic><offsets xml_i="20265" xml_f="20270" txt_i="13243" txt_f="13248">et al</offsets></italic><offsets xml_i="20279" xml_f="20582" txt_i="13248" txt_f="13551">. compared omeprazole with ranitidine in 67 patients who had risk factors for stress ulcer-related bleeding. Results showed significantly more clinically important upper GI bleeding in the ranitidine group than in the omeprazole group due to the inadequate pH control in the ranitidine-treated patients.</offsets></p><p><offsets xml_i="20589" xml_f="20767" txt_i="13552" txt_f="13730">This satisfying control of gastric pH by omeprazole and pantoprazole oral suspension, without facing increased rate of pneumonia; which was previously reported by other studies,[</offsets><xref rid="ref20" ref-type="bibr"><offsets xml_i="20801" xml_f="20803" txt_i="13730" txt_f="13732">20</offsets></xref><xref rid="ref21" ref-type="bibr"><offsets xml_i="20844" xml_f="20846" txt_i="13732" txt_f="13734">21</offsets></xref><offsets xml_i="20853" xml_f="21411" txt_i="13734" txt_f="14292">] could be due to the presence of sodium bicarbonate in the extemporaneous formulation. Although enteric-coating is dissolved by bicarbonate, the alkaline properties of omeprazole suspension appear to protect omeprazole by passing through the stomach and actually aid in the initial control of gastric pH by acting as an antacid. The sodium bicarbonate with pH of 8.4 may stimulate the activation of parietal cells. Such stimulation may improve the pharmacodynamics of the drug by synchronizing the contact time of omeprazole with parietal cells activation.[</offsets><xref rid="ref8" ref-type="bibr"><offsets xml_i="21444" xml_f="21445" txt_i="14292" txt_f="14293">8</offsets></xref><offsets xml_i="21452" xml_f="21453" txt_i="14293" txt_f="14294">]</offsets></p><p><offsets xml_i="21460" xml_f="21781" txt_i="14295" txt_f="14616">We used nonsterile hospital pharmacy manufacturing service at Pharmaceutical Care Department, NRITLD in order to prepare a prescribed medication (omeprazole or pantoprazole as their commercially available dosage form) for individualized patients who are NPO. Thus, they are unable to swallow the solid forms of the drugs.</offsets></p><p><offsets xml_i="21788" xml_f="22150" txt_i="14617" txt_f="14979">An interesting finding of the current study is the control of gastric pH after the first dose of the administered drug in the majority (83.6%) of patients. Average time to achieve mean pH alteration bigger than 1 was 1.24 ± 0.61 days for the total population. It can be concluded from the recent data that there might be no need to pH monitoring after the day 1.</offsets></p><p><offsets xml_i="22157" xml_f="22731" txt_i="14980" txt_f="15554">The current study used an expanded definition for upper GI bleeding. Despite broadening the range of the definition application, which includes even minor self-limited bleeding and bleeding-related to a nasogastric tube trauma, only three patients (5.36%) experienced protocol-defined upper GI bleeding. Two of those who met our secondary end point of upper GI bleeding were among IV pantoprazole-treated patients, and the other one was among the omeprazole suspension group. No significant difference in preventive upper GI bleeding has been indicated between three groups.</offsets></p><p><offsets xml_i="22738" xml_f="23008" txt_i="15555" txt_f="15825">It has been noted that raising gastric pH ≥ 4 could be a risk factor for the development of nosocomial pneumonia. Increasing intragastric pH may allow bacterial (especially Gram-negative bacilli) proliferation in the duodenum and subsequently endotracheal colonization.[</offsets><xref rid="ref21" ref-type="bibr"><offsets xml_i="23042" xml_f="23044" txt_i="15825" txt_f="15827">21</offsets></xref><offsets xml_i="23051" xml_f="23393" txt_i="15827" txt_f="16169">] However, the clinical trials do not seem to support this hypothesis. A double-blind multi-center study that assessed the effect of sucralfate and ranitidine in 1200 critically ill-patients revealed no significant increase in nosocomial pneumonia with ranitidine although it showed a significant decrease in upper GI bleeding with the H2RA.[</offsets><xref rid="ref22" ref-type="bibr"><offsets xml_i="23427" xml_f="23429" txt_i="16169" txt_f="16171">22</offsets></xref><offsets xml_i="23436" xml_f="23839" txt_i="16171" txt_f="16574">] Despite higher mean gastric pH values in omeprazole and pantoprazole suspension group in comparison with IV pantoprazole-treated patients, we found no significant difference in the rate of nosocomial pneumonia among three treatment groups. Our results are in accord with the finding: As yet, no relation between the type of acid-reducing agent and the incidence of nosocomial pneumonia has been found.</offsets></p><sec id="sec2-3"><title></title><sec id="sec3-9"><title><offsets xml_i="23899" xml_f="23923" txt_i="16576" txt_f="16600">Limitations of the study</offsets></title><p><offsets xml_i="23934" xml_f="24495" txt_i="16601" txt_f="17162">(1) Due to several inclusion criteria to meet, we were not able to expand the sample size. (2) Restricted enteral feeding protocol for critically ill patients limited us to hold the enteral feeding for more than 2 h before and 1 h after the sampling. (3) Inefficient method of gastric acid measurement (aspiration technique) used in the study put constraints on sampling, especially in patients with low gastric secretions. (4) High mortality rate of patients at ICUs that was the second important reason causes the patients to stop the trial before the day 14.</offsets></p></sec></sec></sec><sec sec-type="conclusions" id="sec1-5"><title><offsets xml_i="24564" xml_f="24574" txt_i="17166" txt_f="17176">Conclusion</offsets></title><p><offsets xml_i="24585" xml_f="24886" txt_i="17177" txt_f="17478">These findings indicate that extemporaneous preparations of omeprazole and pantoprazole oral suspension are more effective than IV pantoprazole in increasing gastric pH in critically ill-patients without no significant difference in the rate of nosocomial pneumonia between the three treatment groups.</offsets></p></sec></body><back><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Nil</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> None declared.</p></fn></fn-group><ref-list><title>References</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metz</surname><given-names>DC</given-names></name></person-group><article-title>Potential uses of intravenous proton pump inhibitors to control gastric acid secretion</article-title><source>Digestion</source><year>2000</year><volume>62</volume><fpage>73</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">11025353</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fennerty</surname><given-names>MB</given-names></name></person-group><article-title>Pathophysiology of the upper gastrointestinal tract in the critically ill patient: Rationale for the therapeutic benefits of acid suppression</article-title><source>Crit Care Med</source><year>2002</year><volume>30</volume><fpage>S351</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">12072660</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>DJ</given-names></name><name><surname>Griffith</surname><given-names>LE</given-names></name><name><surname>Walter</surname><given-names>SD</given-names></name><name><surname>Guyatt</surname><given-names>GH</given-names></name><name><surname>Meade</surname><given-names>MO</given-names></name><name><surname>Heyland</surname><given-names>DK</given-names></name><etal></etal></person-group><article-title>The attributable mortality and length of intensive care unit stay of clinically important gastrointestinal bleeding in critically ill patients</article-title><source>Crit Care</source><year>2001</year><volume>5</volume><fpage>368</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">11737927</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinberg</surname><given-names>KP</given-names></name></person-group><article-title>Stress-related mucosal disease in the critically ill patient: Risk factors and strategies to prevent stress-related bleeding in the intensive care unit</article-title><source>Crit Care Med</source><year>2002</year><volume>30</volume><fpage>S362</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">12072662</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yasue</surname><given-names>N</given-names></name><name><surname>Guth</surname><given-names>PH</given-names></name></person-group><article-title>Role of exogenous acid and retransfusion in hemorrhagic shock-induced gastric lesions in the rat</article-title><source>Gastroenterology</source><year>1988</year><volume>94</volume><fpage>1135</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">3350282</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamada</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>N</given-names></name><name><surname>Kawano</surname><given-names>S</given-names></name><name><surname>Fusamoto</surname><given-names>H</given-names></name><name><surname>Abe</surname><given-names>H</given-names></name></person-group><article-title>Gastric mucosal hemodynamics after thermal or head injury. A clinical application of reflectance spectrophotometry</article-title><source>Gastroenterology</source><year>1982</year><volume>83</volume><fpage>535</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">7095361</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tryba</surname><given-names>M</given-names></name><name><surname>Cook</surname><given-names>D</given-names></name></person-group><article-title>Current guidelines on stress ulcer prophylaxis</article-title><source>Drugs</source><year>1997</year><volume>54</volume><fpage>581</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">9339962</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>JO</given-names></name><name><surname>Metzler</surname><given-names>MH</given-names></name><name><surname>Palmieri</surname><given-names>MT</given-names></name><name><surname>Huckfeldt</surname><given-names>RE</given-names></name><name><surname>Dahl</surname><given-names>NG</given-names></name></person-group><article-title>A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage</article-title><source>Crit Care Med</source><year>1996</year><volume>24</volume><fpage>1793</fpage><lpage>800</lpage><pub-id pub-id-type="pmid">8917027</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wurzer</surname><given-names>H</given-names></name><name><surname>Schutze</surname><given-names>K</given-names></name><name><surname>Bethke</surname><given-names>T</given-names></name><name><surname>Fischer</surname><given-names>R</given-names></name><name><surname>Luhmann</surname><given-names>R</given-names></name><name><surname>Riesenhuber</surname><given-names>C</given-names></name></person-group><article-title>Efficacy and safety of pantoprazole in patients with gastroesophageal reflux disease using an intravenous-oral regimen. Austrian Intravenous Pantoprazole Study Group</article-title><source>Hepatogastroenterology</source><year>1999</year><volume>46</volume><fpage>1809</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">10430350</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metz</surname><given-names>DC</given-names></name><name><surname>Pratha</surname><given-names>V</given-names></name><name><surname>Martin</surname><given-names>P</given-names></name><name><surname>Paul</surname><given-names>J</given-names></name><name><surname>Maton</surname><given-names>PN</given-names></name><name><surname>Lew</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease</article-title><source>Am J Gastroenterol</source><year>2000</year><volume>95</volume><fpage>626</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">10710049</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lew</surname><given-names>EA</given-names></name><name><surname>Pisegna</surname><given-names>JR</given-names></name><name><surname>Starr</surname><given-names>JA</given-names></name><name><surname>Soffer</surname><given-names>EF</given-names></name><name><surname>Forsmark</surname><given-names>C</given-names></name><name><surname>Modlin</surname><given-names>IM</given-names></name><etal></etal></person-group><article-title>Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome</article-title><source>Gastroenterology</source><year>2000</year><volume>118</volume><fpage>696</fpage><lpage>704</lpage><pub-id pub-id-type="pmid">10734021</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bardhan</surname><given-names>KD</given-names></name></person-group><article-title>Pantoprazole: A new proton pump inhibitor in the management of upper gastrointestinal disease</article-title><source>Drugs Today (Barc)</source><year>1999</year><volume>35</volume><fpage>773</fpage><lpage>808</lpage><pub-id pub-id-type="pmid">12973372</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fitton</surname><given-names>A</given-names></name><name><surname>Wiseman</surname><given-names>L</given-names></name></person-group><article-title>Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders</article-title><source>Drugs</source><year>1996</year><volume>51</volume><fpage>460</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">8882382</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Velayati</surname><given-names>AA</given-names></name><name><surname>Mehrabi</surname><given-names>Y</given-names></name><name><surname>Radmand</surname><given-names>G</given-names></name><name><surname>Maboudi</surname><given-names>AA</given-names></name><name><surname>Jamaati</surname><given-names>HR</given-names></name><name><surname>Shahbazi</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Modification of Acute Physiology and Chronic Health Evaluation II score through recalibration of risk prediction model in critical care patients of a respiratory disease referral center</article-title><source>Int J Crit Illn Inj Sci</source><year>2013</year><volume>3</volume><fpage>40</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">23724384</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Feldman</surname><given-names>M</given-names></name></person-group><source>Pharmacology of untiulcer medications</source><date-in-citation>Last accessed on 2013 Sep 8</date-in-citation><comment>Available from: <uri xlink:type="simple" xlink:href="http://www.uptodate.com/clinicians/content/topic.doptopickey=Ym-odubHEMPOk">http://www.uptodate.com/clinicians/content/topic.doptopickey=Ym-odubHEMPOk</uri></comment></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Jew</surname><given-names>RK</given-names></name></person-group><source>Extemporaneous Formulations for Pediatric, Geriatric, and Special Needs Patients</source><year>2010</year><edition>2nd ed</edition><publisher-loc>Bethesda, MD</publisher-loc><publisher-name>American Society of Health-System Pharmacists</publisher-name></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conrad</surname><given-names>SA</given-names></name><name><surname>Gabrielli</surname><given-names>A</given-names></name><name><surname>Margolis</surname><given-names>B</given-names></name><name><surname>Quartin</surname><given-names>A</given-names></name><name><surname>Hata</surname><given-names>JS</given-names></name><name><surname>Frank</surname><given-names>WO</given-names></name><etal></etal></person-group><article-title>Randomized, double-blind comparison of immediate-release omeprazole oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients</article-title><source>Crit Care Med</source><year>2005</year><volume>33</volume><fpage>760</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">15818102</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pugin</surname><given-names>J</given-names></name><name><surname>Auckenthaler</surname><given-names>R</given-names></name><name><surname>Mili</surname><given-names>N</given-names></name><name><surname>Janssens</surname><given-names>JP</given-names></name><name><surname>Lew</surname><given-names>PD</given-names></name><name><surname>Suter</surname><given-names>PM</given-names></name></person-group><article-title>Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic “blind” bronchoalveolar lavage fluid</article-title><source>Am Rev Respir Dis</source><year>1991</year><volume>143</volume><fpage>1121</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">2024824</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lasky</surname><given-names>MR</given-names></name><name><surname>Metzler</surname><given-names>MH</given-names></name><name><surname>Phillips</surname><given-names>JO</given-names></name></person-group><article-title>A prospective study of omeprazole suspension to prevent clinically significant gastrointestinal bleeding from stress ulcers in mechanically ventilated trauma patients</article-title><source>J Trauma</source><year>1998</year><volume>44</volume><fpage>527</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">9529184</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernández</surname><given-names>C</given-names></name><name><surname>el-Ebiary</surname><given-names>M</given-names></name><name><surname>Gonzalez</surname><given-names>J</given-names></name><name><surname>de la Bellacasa</surname><given-names>JP</given-names></name><name><surname>Montón</surname><given-names>C</given-names></name><name><surname>Torres</surname><given-names>A</given-names></name></person-group><article-title>Relationship between ventilator-associated pneumonia and intramucosal gastric pHi: A case-control study</article-title><source>J Crit Care</source><year>1996</year><volume>11</volume><fpage>122</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">8891963</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>HY</given-names></name><name><surname>He</surname><given-names>LX</given-names></name><name><surname>Hu</surname><given-names>BJ</given-names></name><name><surname>Wang</surname><given-names>BQ</given-names></name><name><surname>Zhang</surname><given-names>XY</given-names></name><name><surname>Chen</surname><given-names>XH</given-names></name><etal></etal></person-group><article-title>The impact of gastric colonization on the pathogenesis of ventilator-associated pneumonia</article-title><source>Zhonghua Nei Ke Za Zhi</source><year>2004</year><volume>43</volume><fpage>112</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15059408</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>D</given-names></name><name><surname>Guyatt</surname><given-names>G</given-names></name><name><surname>Marshall</surname><given-names>J</given-names></name><name><surname>Leasa</surname><given-names>D</given-names></name><name><surname>Fuller</surname><given-names>H</given-names></name><name><surname>Hall</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group</article-title><source>N Engl J Med</source><year>1998</year><volume>338</volume><fpage>791</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">9504939</pub-id></element-citation></ref></ref-list></back></article>